'Stable disease' diaporamas de présentation

2013 ASH Highlights in Multiple Myeloma Kenneth C. Anderson, M.D.

2013 ASH Highlights in Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute. Conflict of Interest: Kenneth C. Anderson, M.D.

951 views • 63 slides

RESTAGING AFTER NEOADJUVANT THERAPY

731 views • 48 slides

Adenoid Cystic Carcinoma: A clinical and molecular review

Adenoid Cystic Carcinoma: A clinical and molecular review. Patrick Ha, MD FACS Associate Professor, Johns Hopkins Department of Otolaryngology Johns Hopkins Head and Neck Surgery GBMC Head and Neck Grand Rounds, November 1, 2013. Disclosures. Research Funding: NIH/NIDCR

923 views • 48 slides

Tumor Markers

Tumor Markers. Overview. Cancer remains the second leading cause of death in the USA, behind heart disease, with an estimated 1,437,180 new cases & 565,650 deaths in 2008 alone. It is expected that malignancies of prostate & breast origin will be

1.78k views • 46 slides

Novel treatment options for Waldenstrom Macroglobulinemia

Novel treatment options for Waldenstrom Macroglobulinemia. Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA. Ghobrial et al, Lancet Oncol 2004, Treon et al, Blood 2009. MYD88 in WM. Treon et al, NEJM 2012.

1.27k views • 37 slides

Towards a Consensus in Measuring Outcomes in New Agents for Prostate Cancer

508 views • 34 slides

Progression after checkpoint inhibitors. What is next?

330 views • 32 slides

Therapeutic Drug Monitoring (TDM) of Tyrosine Kinase Inhibitors (TKI) in MRCC

686 views • 30 slides

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs. E. Efthimiou , S Mudan On behalf of the Sarcoma Group The Royal Marsden Hospital. Incidence. Gastrointestinal Stromal Tumours GIST are the most common mesenchymal tumours of the gastrointestinal tract.

439 views • 30 slides

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Dejka M. Steinert, MD

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Dejka M. Steinert, MD. Rationale for Study. Phase I study: 2/10 (20%) evaluable sarcoma patients responded One patient each Chondrosarcoma Leiomyosarcoma

381 views • 18 slides

Cancer T reatment Options

285 views • 16 slides

Systemic Lupus Erythematosus and Pregnancy

Systemic Lupus Erythematosus and Pregnancy. Andres Quiceno, MD Rheumatology. Case Presentation 28 y/o WF with PMHx of SLE diagnosed in 1993 when presented with thrombocytopenia, arthritis, malar rash and +ANA. Patient was clinically in remission for the last 2 years on Plaquenil.

371 views • 12 slides

Lower Gastrointestinal NET C linical case One patient and how many doctors ?

232 views • 12 slides

MOH KS management guidelines

MOH KS management guidelines. Jane Bates Tiyanjane Clinic, QECH October 2009. Criteria for vincristine. Clinical diagnosis of KS. Tested for HIV. On ARVs for at least 3 months. advanced and / or progressive disease (check FBC) - consider vincristine. improving and / or stable disease

156 views • 8 slides

Use of KRN330, A Fully Human Antibody Against A33, in Combination with

Abstract ID #534. Use of KRN330, A Fully Human Antibody Against A33, in Combination with Irinotecan for Patients with Metastatic Colorectal Cancer (mCRC) J.C. Bendell, 1 J.L. Marshall, 2 J. Berlin, 3 H.S. Hochster, 4

122 views • 1 slides